BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dostarlimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dostarlimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05526989-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT05526989)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: Study of the Combination Dostarl
 imab With Niraparib In Patients With Penile Carcinoma\nEstimated primary c
 ompletion: November 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dostarlimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05526989
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06567782-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20261123
DTEND;VALUE=DATE:20261124
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06567782)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: A Study of Neoadjuvant Dostarlim
 ab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously U
 ntreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellit
 e Stable (MSS) Colon Cancer\nEstimated primary completion: 23 November 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06567782
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03981796-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT03981796)
DESCRIPTION:Dostarlimab\, phase 3\, Endometrial Cancer.\nStudy: A Study to 
 Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carbo
 platin-paclitaxel in Participants With Recurrent or Primary Advanced Endom
 etrial Cancer\nEstimated primary completion: 26 November 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03981796
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165772-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT04165772)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: Study of In
 duction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair De
 ficient Solid Tumors\nEstimated primary completion: 30 November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04165772
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238635-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06238635)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: Dostarlimab and Cobolimab in Adv
 anced Cervical Cancer\nEstimated primary completion: 1 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06238635
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317311-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06317311)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: A Study of 
 Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Partici
 pants With Primary Advanced or Recurrent Endometrial Cancer\nEstimated pri
 mary completion: 14 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06317311
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04446351-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dostarlimab: Phase 1 readout est. (NCT04446351)
DESCRIPTION:Dostarlimab\, phase 1.\nStudy: Study of the Safety and Effectiv
 eness of GSK6097608 in Participants With Advanced Solid Tumors\nEstimated 
 primary completion: 31 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04446351
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879717-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Dostarlimab: Phase 1/2 readout est. (NCT06879717)
DESCRIPTION:Dostarlimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Wi
 thout Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06879717
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06897527-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Dostarlimab: Phase 4 readout est. (NCT06897527)
DESCRIPTION:Dostarlimab\, phase 4\, Endometrial Cancer.\nStudy: A Study to 
 Evaluate the Safety of Dostarlimab in Adult Participants in India With Rec
 urrent or Advanced Endometrial Cancer (EC)\nEstimated primary completion: 
 13 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dost
 arlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06897527
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04774419-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT04774419)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: Radiation a
 nd TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Rece
 ive Surgery\nEstimated primary completion: February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04774419
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04837209-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT04837209)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: Radiation\, Immunotherapy and PA
 RP Inhibitor in Triple Negative Breast Cancer\nEstimated primary completio
 n: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 ostarlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04837209
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05784012-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dostarlimab: Phase 1/2 readout est. (NCT05784012)
DESCRIPTION:Dostarlimab\, phase 1/2.\nStudy: Two-cohort Study of Niraparib 
 and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck
  Squamous Cell Carcinoma\nEstimated primary completion: March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05784012
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02817633-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Dostarlimab: Phase 1 readout est. (NCT02817633)
DESCRIPTION:Dostarlimab\, phase 1.\nStudy: A Study of TSR-022 in Participan
 ts With Advanced Solid Tumors (AMBER)\nEstimated primary completion: 1 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dostarlimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0281
 7633
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05819892-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Dostarlimab: Phase 1 readout est. (NCT05819892)
DESCRIPTION:Dostarlimab\, phase 1\, Endometrial Cancer.\nStudy: Phase I Tri
 al Testing the Safety and Tolerability of Chemoradiation Followed by Chemo
 therapy + Dostarlimab for Stage IIIC\, Node Positive\, Endometrial Cancer\
 nEstimated primary completion: 1 March 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05819892
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04387084-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dostarlimab: Phase 1 readout est. (NCT04387084)
DESCRIPTION:Dostarlimab\, phase 1.\nStudy: Short-term Fasting Prior to PD-1
 /PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy\nEs
 timated primary completion: 31 March 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04387084
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05559879-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dostarlimab: Phase 1/2 readout est. (NCT05559879)
DESCRIPTION:Dostarlimab\, phase 1/2\, Endometrial Cancer.\nStudy: Cabozanti
 nib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma\nEstimated pri
 mary completion: April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/dostarlimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05559879
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04701307-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT04701307)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: Niraparib and Dostarlimab for th
 e Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine 
 Carcinomas\nEstimated primary completion: 30 April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04701307
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03651206-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dostarlimab: Phase 2/3 readout est. (NCT03651206)
DESCRIPTION:Dostarlimab\, phase 2/3.\nStudy: Recurrent Ovarian CarcinoSarco
 ma Anti-pd-1 Niraparib\nEstimated primary completion: June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03651206
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796907-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Dostarlimab: Phase 1/2 readout est. (NCT06796907)
DESCRIPTION:Dostarlimab\, phase 1/2.\nStudy: A Study of Mocertatug Rezeteca
 n in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEH
 OLD-2)\nEstimated primary completion: 21 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06796907
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06023862-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06023862)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: A Three-arm Randomized Phase II 
 Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemothe
 rapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENG
 OT-ov80 Study)\nEstimated primary completion: 31 August 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06023862
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065462-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Dostarlimab: Phase 1/2 readout est. (NCT06065462)
DESCRIPTION:Dostarlimab\, phase 1/2.\nStudy: Safety and Efficacy of Targeti
 ng PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100\nEsti
 mated primary completion: 1 October 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06065462
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06640049-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20271024
DTEND;VALUE=DATE:20271025
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06640049)
DESCRIPTION:Dostarlimab\, phase 2\, Rectal Cancer.\nStudy: A Study of Dosta
 rlimab in Participants With Untreated Locally Advanced Rectal Cancer in Ch
 ina\nEstimated primary completion: 24 October 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06640049
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830239-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06830239)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: Phase II Study of Neoadjuvant Do
 starlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resect
 able Colon Cancer\nEstimated primary completion: December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06830239
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757244-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20280218
DTEND;VALUE=DATE:20280219
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06757244)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: DOVIPA\, a Study Evaluating Effi
 cacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreat
 ic Cancer\nEstimated primary completion: 18 February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06757244
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07336147-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20280622
DTEND;VALUE=DATE:20280623
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT07336147)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: Dostarlimab\, Cisplatin and Etop
 oside in Combination With Radiotherapy in Sandwich Sequence for Small Cell
  Neuroendocrine Cervical Carcinoma\nEstimated primary completion: 22 June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0733614
 7
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05239546-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT05239546)
DESCRIPTION:Dostarlimab\, phase 2\, Rectal Cancer.\nStudy: Single Arm Study
  of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair 
 Colon Cancers\nEstimated primary completion: 30 June 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05239546
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06256588-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT06256588)
DESCRIPTION:Dostarlimab\, phase 3.\nStudy: A Study of Dostarlimab vs Placeb
 o After Chemoradiation in Adult Participants With Locally Advanced Unresec
 ted Head and Neck Squamous Cell Carcinoma\nEstimated primary completion: 3
 0 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dostarli
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06256588
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381777-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT07381777)
DESCRIPTION:Dostarlimab\, phase 2\, Rectal Cancer.\nStudy: XELOX Plus DoSTA
 Rlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemor
 adiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Pati
 ents\nEstimated primary completion: 1 July 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07381777
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05855811-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20280726
DTEND;VALUE=DATE:20280727
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT05855811)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: PREventing Second Cancers With D
 OSTARlimab\nEstimated primary completion: 26 July 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05855811
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03833479-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT03833479)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: TSR-042 as Maintenance Therapy f
 or Patients With High-risk Locally Advanced Cervical Cancer After Chemo-ra
 diation\nEstimated primary completion: 31 July 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03833479
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06059495-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06059495)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: DEWI: Watch-and-Wait With Dostar
 limab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study\nE
 stimated primary completion: 1 September 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06059495
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333314-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06333314)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: Dostarlimab for Locally Advanced
  or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
 \nEstimated primary completion: October 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06333314
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06551142-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Dostarlimab: Phase 1 readout est. (NCT06551142)
DESCRIPTION:Dostarlimab\, phase 1.\nStudy: A Study of GSK5764227 in Partici
 pants With Advanced Solid Tumors (EMBOLD)\nEstimated primary completion: 1
 6 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dosta
 rlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06551142
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013851-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT07013851)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: Clinical Tr
 ial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patien
 ts With MMRd/MSI-H Stage II-III Endometrial Cancer\nEstimated primary comp
 letion: 1 March 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dostarlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07013851
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05855200-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20290319
DTEND;VALUE=DATE:20290320
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT05855200)
DESCRIPTION:Dostarlimab\, phase 3.\nStudy: Study of Perioperative Dostarlim
 ab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable 
 Colon Cancer\nEstimated primary completion: 19 March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05855200
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684599-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20290723
DTEND;VALUE=DATE:20290724
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT07684599)
DESCRIPTION:Dostarlimab\, phase 3\, Endometrial Cancer.\nStudy: A Study to 
 Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants
  With MMRp Endometrial Cancer (BEHOLD-Endometrial02)\nEstimated primary co
 mpletion: 23 July 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dostarlimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07684599
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05700721-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT05700721)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: Phase II Trial of the PARP Inhib
 itor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Ca
 ncers With Active Progressing Brain Metastases (STARLET)\nEstimated primar
 y completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dostarlimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05700721
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740720-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20300313
DTEND;VALUE=DATE:20300314
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT07740720)
DESCRIPTION:Dostarlimab\, phase 3\, Rectal Cancer.\nStudy: A Study of the D
 uration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Micr
 osatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer\nEstima
 ted primary completion: 13 March 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07740720
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108270-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT07108270)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: A Study of 
 Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Particip
 ants With Primary Advanced or Recurrent Endometrial Cancer (EC)\nEstimated
  primary completion: 31 March 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07108270
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115927-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT07115927)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: pReOperativ
 e Dostarlimab and Novel Therapies in EndOmetrial Cancer\nEstimated primary
  completion: 30 April 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dostarlimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07115927
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07408063-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT07408063)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: A Comprehensive Multiomic Biomar
 ker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Re
 sponse and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous
  Cell Carcinoma (HNSCC)\nEstimated primary completion: 30 June 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07408063
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652515-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Dostarlimab: Phase 4 readout est. (NCT07652515)
DESCRIPTION:Dostarlimab\, phase 4\, Endometrial Cancer.\nStudy: A Study to 
 Evaluate the Safety of Dostarlimab in Adult Participants in India With Pri
 mary Advanced or Recurrent Endometrial Cancer\nEstimated primary completio
 n: 30 August 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/do
 starlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07652515
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07860450-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20301105
DTEND;VALUE=DATE:20301106
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT07860450)
DESCRIPTION:Dostarlimab\, phase 3\, Endometrial Cancer.\nStudy: Two Part (P
 hase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclita
 xel in Participants With Primary Advanced or Recurrent Endometrial Cancer\
 nEstimated primary completion: 5 November 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07860450
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2162@assetmemo.bio
DTSTAMP:20261121T004022Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuvant and Per
 sonalized Adaptive Novel Agents to Treat Breast Cancer\nEstimated primary 
 completion: December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dostarlimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT01042379
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
